Arax Advisory Partners’s Mineralys Therapeutics MLYS Stock Holding History

Arax Advisory Partners’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.72K	Buy	286 +217	+314%	+$5.95K	﹤0.01%	4441
2026 Q1	$1.87K	Sell	69 -40	-37%	-$1.17K	﹤0.01%	3126
2025 Q4	$3.96K	Sell	109 -161	-60%	-$6.46K	﹤0.01%	2974
2025 Q3	$10.2K	Buy	+270	New	+$5.84K	﹤0.01%	2585
2025 Q1	–	Sell	-108	Closed	-$1.33K	–	2901
2024 Q4	$1.33K	Hold	108	–	–	﹤0.01%	2105
2024 Q3	$1.31K	Hold	108	–	–	﹤0.01%	2178
2024 Q2	$1.26K	Buy	+108	New	+$1.36K	﹤0.01%	2104

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Arax Advisory Partners's MLYS Position: Q2 2026 in Review

Arax Advisory Partners increased its Mineralys Therapeutics (MLYS) stake by 314% in Q2 2026, buying an estimated $5.95K and bringing the position to 286 shares worth $7.72K. The position accounts for ﹤0.01% of the portfolio, ranked #4441.

Arax Advisory Partners first reported a position in MLYS in Q2 2024 and has held it in 7 quarters since. The position peaked at $10.2K in Q3 2025. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

Arax Advisory Partners held 286 shares of Mineralys Therapeutics worth $7.72K as of Q2 2026.
Arax Advisory Partners bought 217 Mineralys Therapeutics shares in Q2 2026, an estimated $5.95K.
Mineralys Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4441 holding.
Arax Advisory Partners first reported a position in Mineralys Therapeutics in Q2 2024 and has held it in 7 quarters since.
Arax Advisory Partners's Mineralys Therapeutics position peaked at $10.2K in Q3 2025.
226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.